Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy
Fig 6
Patient data best-fit of irinotecan PK model.
Each subplot represents an individual patient dataset, fit to the model independently. (A) shows the fit of irinotecan plasma concentration, (B) shows that of SN38, the active metabolite of irinotecan.